• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Meta-Analysis: Non-Alcoholic Fatty Liver Disease: Is It More Prevalent Than We Think?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Non-alcoholic fatty liver disease (NAFLD) is a common liver disease, and a leading cause of liver related morbidity and mortality
  • Riazi et al. (Lancet Gastroenterology and Hepatology, 2022) examined NAFLD worldwide temporal trends

METHODS:

  • Systematic review and meta-analysis
  • Inclusion criteria
    • Included observational cross-sectional or longitudinal studies
    • Studies done in
      • General adult populations | NAFLD diagnosed using an imaging method | Absence of excessive alcohol consumption and viral hepatitis
  • Study design
    • Random-effects meta-analysis was used to calculate overall and sex-specific pooled effect estimates
  • Primary outcomes
    • Prevalence and incidence of NAFLD

RESULTS:

  • Prevalence analysis: 72 studies | 1,030,160 individuals from 17 countries
  • Incidence analysis: 16 studies | 381,765 individuals from 5 countries
  • There was considerable heterogeneity between studies of both
    • NAFLD prevalence: I2=99.9%
    • NAFLD incidence: I2=99.9%

NAFLD Prevalence

  • Estimated overall prevalence of NAFLD worldwide
    • 32.4% (95% CI, 29.9 to 34.9)
  • Prevalence increased significantly over time
    • ≤2005: 25.5% (95% CI, 20.1 to 31.0)
    • ≥2016: 37.8% (95% CI, 32.4 to 43.3)
    • P=0.013
  • Overall prevalence of NAFLD was significantly higher in men than in women
    • Men: 39.7% (95% CI, 36.6 to 42.8)
    • Women: 25.6% (95% CI, 22.3 to 28.8)
    • P<0.0001

NAFLD Incidence

  • Estimated overall incidence of NAFLD worldwide
    • 46.9 (95% CI, 36.4 to 57.5) cases per 1000 person-years
  • Overall incidence of NAFLD was significantly higher in men than in women
    • Men: 70.8 (95% CI, 48.7 to 92.8) cases per 1000 person-years
    • Women: 29.6 (95% CI, 20.2 to 38.9) cases per 1000 person-years
    • P<0.0001

CONCLUSION:

  • In this meta-analysis with a populations sample of over 1 million individuals, the prevalence of NAFLD was higher than originally thought, and appears to be increasing
  • The disease had a significantly higher incidence and prevalence among men, compared to women
  • The authors state

Greater awareness of NAFLD and the development of cost-effective risk stratification strategies are warranted to address the growing burden of NAFLD

Learn More – Primary Sources:

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Nonalcoholic Fatty Liver Disease (NAFLD) – Diagnosis and Management
Does Bariatric Surgery Reduce Cardiovascular Risk for Patients with NASH and Obesity?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site